Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4A, 20-093 Lublin, Poland.
Department of Biochemistry and Biotechnology, Faculty of Pharmacy, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland.
Bioorg Chem. 2020 Apr;97:103676. doi: 10.1016/j.bioorg.2020.103676. Epub 2020 Feb 18.
The two series of thiosemicarbazone derivatives with thiazolidine-2,4-dione (TZD) core were designed and synthesized. The antimycobacterial activity of the target compounds was tested against Mycobacterium tuberculosis H37Ra by broth microdilution method with resazurin as an indicator of the metabolic activity of mycobacteria. Conducted studies revealed antimycobacterial activity in the concentration range of 0.031-64 µg/ml for 31 synthesized derivatives with TZD core. The highest antimycobacterial activity (MIC = 0.031-0.125 µg/ml) was demonstrated for the new group of compounds: TZD-based hybrids with 4-unsubstituted thiosemicarbazone substituent. Furthermore, all the tested compounds within this group were characterized by low cytotoxicity. Among tested compounds, two compounds are the most promising potential antimycobacterial agents since they not only show very low MIC values, but also non-toxicity against Vero cells at tested concentration range. High effectiveness and safety of these synthesized compounds makes them promising candidates as antimycobacterial agents.
设计并合成了两个具有噻唑烷-2,4-二酮(TZD)核心的硫代缩氨基脲衍生物系列。采用含有 Resazurin 的肉汤微量稀释法,以分枝杆菌的代谢活性为指示剂,对目标化合物进行了抗结核分枝杆菌 H37Ra 的活性测试。研究结果表明,在所合成的 31 个具有 TZD 核心的衍生物中,有 31 个在 0.031-64μg/ml 的浓度范围内具有抗分枝杆菌活性。具有 4-未取代的硫代缩氨基脲取代基的 TZD 基杂合体的新组化合物表现出最高的抗分枝杆菌活性(MIC=0.031-0.125μg/ml)。此外,该组所有测试的化合物均表现出低细胞毒性。在所测试的化合物中,有两种化合物是最有前途的潜在抗分枝杆菌药物,因为它们不仅显示出非常低的 MIC 值,而且在测试浓度范围内对 Vero 细胞也没有毒性。这些合成化合物的高效性和安全性使它们成为有前途的抗分枝杆菌药物候选物。